Double-Refractory vs Double-Exposed CLL - Dr. Matthew Davids and Dr. Inhye Ahn

28 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Patients with double-refractory disease, which is resistant to both BTK and BCL2 inhibitors, have worse outcomes than patients who have been treated with both drugs but have not developed resistance (double-exposed).

Dr. Inhye Ahn from Dana-Farber Cancer Institute and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting in 2024.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/08/double-refractory-vs-double-exposed-cll/

__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook: https://www.facebook.com/CLLsociety
Twitter: https://twitter.com/CllSociety
LinkedIn: https://www.linkedin.com/company/cll-society/
Categoria
Oncology
Commenta per primo questo video.

Prossimo